Prescriber's Corner
Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
Nancy M. Nix, PharmD, BCPS, BCOP, and Kirk Braun*
From St. Joseph’s/Candler Health System, South Carolina Cancer Specialists, Hilton Head, South Carolina; University of Georgia College of Pharmacy, Athens, Georgia
Authors' disclosures of potential conflicts of interest are found at the end of this article.
Correspondence to: Nancy M. Nix, PharmD, BCPS, BCOP, South Carolina Cancer Specialists, PO Box 21824, Hilton Head, SC 29925.
E-mail: nixna@sjchs.org
J Adv Pract Oncol 2014;5:47-50# |
DOI: 10.6004/jadpro.2014.5.1.10 |
© 2014 Harborside Press®
For access to the full length article, please
sign in.